Commercial-stage immunotherapy company developing next-generation therapies that drive multiple innate and adaptive immune mechanisms, including the IL-15 superagonist ANKTIVA and Ad5/Ad26-based vaccine platforms, against cancer and infectious disease.
FDA expands ANKTIVA approval to BCG-unresponsive high-grade papillary-only bladder cancer
The FDA expanded approval of Anktiva (nogapendekin alfa inbakicept-pmln), given with BCG, to adults with BCG-unresponsive, high-grade papillary-only bladder cancer - the first FDA-approved treatment specifically for that population.
Founder, Executive Chairman and Global Chief Medical Officer
President and Chief Executive Officer